pISSN 1226-6051
eISSN 2508-786X

Table. 3.

Table. 3.

Incidence and hazard of specific cancers in patients with T2DM on antidiabetic monotherapy

 CancersMetformin (n=5,825)Sulfonyl urea (n=3,225)Unadjusted HR (95% CI)Adjusted HR (95% CI)
Total incidence740 (12.70%, 100%)696 (21.58%, 100%)0.82 (0.74-0.91)*0.74 (0.66-0.83)*
Colorectum74 (1.27%, 10.00%)80 (1.37%, 11.49%)0.75 (0.54-1.04)0.73 (0.52-1.04)
Lung52 (0.89%, 7.03%)80 (1.37%, 11.49%)0.48 (0.34-0.69)*0.46 (0.31-0.66)*
Liver98 (1.68%, 13.24%)151 (4.68%, 21.70%)0.47 (0.36-0.61)*0.41 (0.31-0.54)*
Breast40 (0.69%, 5.41%)12 (0.37%, 1.72%)2.31 (1.20-4.45)*1.50 (0.75-2.99)
Stomach58 (1.00%, 7.84%)81 (2.51%, 11.64%)0.53 (0.37-0.75)*0.51 (0.35-0.73)*
Bladder24 (0.41%, 3.24%)12 (0.37%, 1.72%)1.66 (0.81-3.40)1.83 (0.86-3.89)
Kidney12 (0.21%, 1.62%)10 (0.31%, 1.44%)0.95 (0.39-2.28)1.00 (0.39-2.59)

Note:

p<0.05. Adjusted HRs were derived after adjustment for age, sex CCI, hyperlipidemia, hypertension, pancreatitis, morbid obesity, alcohol use disorders, smoking-related diagnoses, and duration of follow-up.

Korean J Clin Pharm 2019;29:186-92 https://doi.org/10.24304/kjcp.2019.29.3.186
© 2019 Korean J Clin Pharm